Background and Aims: Gene expression analysis of colon biopsies using high-density oligonucleotide microarray can contribute to the understanding of local pathophysiological alterations and to functional classification of precancerous adenoma, different stage colorectal carcinomas (CRC) and inflammatory bowel diseases (IBD).
Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples.
No sample metadata fields
View SamplesMost of the breast cancer samples used in clinical research contain multiple cell types other than epithelial cells alone. The non-epithelial cell types have have a substantial effect on the gene expression-profile, which is used to define molecular subtypes of the tumours. The purpose of this data set is to retrieve gene-expression profile within tumour epithelial cells. We collected 9 breast cancer epithelial cell lines and 5 tumour sampes from which epithelial cells were sorted and enriched using BerEp4 antibody coated beads. We profiled the mRNA expression level of these samples and classified probe sets into epithelial genes which were those genes with present calls in at least 50% of the samples. Then we derived an 23-gene signature based on only the epithelial genes to stratify breast cancer.
Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.
Specimen part
View SamplesComparison of transcriptional profiles of human umbilical vein endothelial cells (HUVECs) expressing wild-type vs. VM-causative mutant forms of TIE2/TEK.
Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB.
Specimen part
View SamplesParkinsons disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or prevent progression of the disease. We performed a transcriptome-wide scan in 105 individuals to interrogate the molecular processes perturbed in cellular blood of patients with early-stage PD. The molecular marker here identified is strongly associated with risk of PD in 66 samples of the training set (third tertile cross-validated odds ratio of 5.7 {P for trend 0.005}). It is further validated in 39 independent test samples (third tertile odds ratio of 5.1 {P for trend 0.04}). The genes differentially expressed in patients with PD, or Alzheimers or progressive supranuclear palsy offer unique insights into disease-linked processes detectable in peripheral blood. Combining gene expression scans in blood and linked clinical data will facilitate the rapid characterization of candidate biomarkers as demonstrated here with respect to PD.
Molecular markers of early Parkinson's disease based on gene expression in blood.
No sample metadata fields
View SamplesThis SuperSeries is composed of the SubSeries listed below.
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.
Sex, Age, Specimen part
View SamplesWe show that an excess of VEGF-B protects the heart via adaptive cardiac hypertrophy and increased coronary arterial reserve, and by inducing a shift from lipid to glucose metabolism.
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart.
Sex, Age, Specimen part
View SamplesThe composition of the matrix molecules is important in in vitro cell culture experiments of e.g. human cancer invasion and vessel formation. Currently, the mouse Engelbreth-Holm-Swarm (EHS) sarcoma -derived products, such as Matrigel, are the most commonly used tumor microenvironment mimicking (TMEM) matrices for experimental studies. However, since Matrigel is non-human in origin, its molecular composition does not accurately simulate human TMEM and we expect myogel to be more natural environment for human cancer cells. The environment may have crucial impact on cell behavior and gene expression.
A novel human leiomyoma tissue derived matrix for cell culture studies.
Cell line
View SamplesEvidence suggests that BRCA1 mutation associated tumors have increased sensitivity to DNA damaging agents like cisplatin. Sporadic triple negative breast cancers (TNBC) have many phenotypic similarities to BRCA1 tumors and may have a similar sensitivity to cisplatin. We tested the efficacy of cisplatin monotherapy in 28 TNBC patients in a single arm neoadjuvant trial with outcome measured by pathologic treatment response quantified using the Miller-Payne scale.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Age, Disease stage
View SamplesThis SuperSeries is composed of the SubSeries listed below.
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.
Sex, Age, Specimen part, Disease
View SamplesGenome-wide transcriptome analysis of expression changes in Globus Pallidus interna (GPi) from Parkinson's disease brain tissue versus control brain tissue.
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.
Sex, Specimen part, Disease, Disease stage
View Samples